Founded in the UK in 2002, Pharmidex provides translational solutions in state-of-the-art facilities in London and Hatfield offering high-quality bespoke experimental data to support drug discovery and development. We have comprehensive in-house laboratory facilities as well as extensive in vitro and in vivo assay options. This enables us to provide tailored studies designed to meet individual project needs. Through extensive knowledge of drug discovery and development, Pharmidex has been able to deliver a high level of customer satisfaction and forge several strategic international alliances, focusing on operations in the following areas: - In vitro ADMET - In vivo pharmacology - CNS drug discovery - Bioanalysis and metabolite Identification - Oncology and bioimaging - Cerense drug delivery - Toxicology - Pharmacokinetics - Physicochemical properties
Our bioanalysis service is focused on enabling our clients to make good decisions on progression of compounds towards candidate selection and beyond.
We believe the acquisition and timely delivery of high-quality bioanalytical data from in vitro and in vivo ADMET studies is critical to enable clients to identify the best candidates for progression into development.
To meet this demand we have established a team of scientists in modern laboratories in Hatfield with access to state-of-the-art equipment, including highly sensitive QTof and triple quadrupole mass spectrometry and UHPLC. The team has extensive experience in bioanalytical techniques and in the ADMET field as a whole, gained both from current positions at Pharmidex and previously at several of the world’s leading pharmaceutical R&D organisations.
Our philosophy is to work in a collaborative way with each client to develop a flexible, fit-for-purpose approach to suit their specific requirements. We are always happy to discuss study design and assist with data interpretation as necessary.
The World Health Organisation estimates that mental, neurological and substance use disorders account for 14% of the total global burden of disease.
Currently there are no disease-modifying therapies for the majority of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. There is an unmet clinical need to find therapeutic agents that offer a benefit beyond the symptomatic relief of the disease.
A limited understanding of the pathophysiology that underlies most psychiatric disorders means current medicaments for diseases such as schizophrenia, bipolar disorder or major depressive disorder only manage some aspects of the symptomatology and are only effective in a limited proportion of the patients.
Pharmidex is committed to supporting industry and academic partners in their search for developing safer and more efficacious CNS treatments. We offer our drug development expertise in CNS and provide a comprehensive research platform of techniques, including behaviour and neurochemistry analyses, in addition to bioanalysis.
Microsomal Metabolic Stability Assay
Microsomal glucuronidation assay
Hepatocyte Metabolic Stability Assay
S9 Metabolic Stability Assay
Cytosol Metabolic Stability Assay
Plasma Stability Assay
Blood Stability Assay
Plasma Protein Binding Assay
Blood Binding Assay
Cell Culture Media Binding Assay
Brain Tissue Binding Assay
Tissue Binding Assay
Brain Stability Assay
Tissue Stability Assay
Urine Stability Assay
Red Blood Cell Partitioning Assay
MDR1-MDCK Permeability Assay
Caco-2 Permeability Assay
Partition Coefficient (Log D) Assay
To address the challenges encountered within drug discovery and development Pharmidex offers an extensive suite of absorption, distribution, metabolism, excretion and toxicity/pharmacokinetic (ADMET) in vitro assay solutions.
Pharmidex offers a range of in vivo validated assays to assess the therapeutic potential of anti-obesity and anti-diabetic agents.
Genetic and diet-induced rodent models are used to determine the efficacy of candidate therapeutics and inform mechanism of action. Studies are managed by experts with high records of success in world-leading pharmaceutical companies.
For anti-obesity agents, measurements include energy expenditure, metabolic rate, body composition and food intake, such as impact of pair feeding.
For anti-diabetic agents, glucose tolerance, insulin sensitivity and/or insulin tolerance assessments are coupled with a range of plasma biomarkers to evaluate efficacy and mechanism of action.
Various administration routes are available and studies may be coupled with pharmacokinetic measurements to inform on PK/PD, providing a robust pre-clinical package for pre-development assessment and project decisions.
Data analysis and study reports are of the highest standard, and may be included in Investigational New Drug (IND) applications.
An understanding of simple physicochemical properties can help drive the lead optimisation and lead identification phases of drug discovery.
Many pharmacologically active molecules fail to progress as a result of suboptimal properties, which are sometimes related to inappropriate physicochemical characteristics.
At Pharmidex we can conduct the following analyses to determine whether your compound of interest has the optimal physicochemical properties for progression into development:
Our MHRA- and OLAW-accredited toxicology department will help you with your preclinical and other early-stage product development needs to assure product safety and regulatory compliance.
Our knowledgeable and experienced scientists will design and implement standard and customised bespoke discovery toxicology or regulatory toxicology studies in a timely and professional manner, helping you to progress to Investigational New Drug (IND) and New Drug Application (NDA) submissions.
Depending on your requirements, various administration routes can be utilised, such as oral, intravenous, subcutaneous, topical and intraperitoneal. Pharmidex has state-of-the art facilities to perform not only toxicity studies, but any surgical preparation, such as multiple cannulation for serial sampling during toxicokinetic studies. This can be useful for critical evaluation of drug disposition at toxicologic doses and also to establish the relationships between toxicokinetic values and the occurrence and time course of toxic events to save your time and resources.
Your toxicity study will be performed according to the agreed Protocol, Testing Facility Standard Operating Procedures, OLAW guidelines and British Home Office regulations. If requested, your study can be compliant with the Good Laboratory Practice Regulations 1999 (S.I. No. 3106), as amended by the 2004 regulations (S.I. No. 994), which are based on the principles of good laboratory practice as adopted by the Organisation for Economic Co-operation and Development (OECD), ENV/MC/CHEM (98) 17.
OECD guidelines that will be used for your study designs may include the following:
Your studies will be quickly initiated and you can count on report preparation that will meet your milestones or deadlines. Customer satisfaction, high quality and flexibility are core values of Pharmidex’s corporate philosophy, which will help to fast-forward your drug discovery programmes, assist in candidate selection and to support the first-in-human studies.
Respiratory diseases are increasing in prevalence around the globe and affect millions of people annually.
Current World Health Organisation estimates indicate that currently 235 million people worldwide suffer with asthma, 64 million with chronic obstructive pulmonary disease (COPD) and millions with allergic rhinitis. These diseases put a huge burden on individuals and society as the unmet medical need is substantial, with patients often remaining symptomatic for many years despite using the best available therapies.
Pharmidex is committed to supporting industry and academic partners in their search for developing safer and more efficacious treatment for Respiratory disease. We offer our drug development expertise in Respiratory therapeutics and provide a comprehensive research service, including pharmacodynamic assays and translatable respiratory disease models, in addition to bioanalysis.
Bioimaging is a non-invasive process that allows in vivo imaging of biological changes in the body in response to drug treatment in progressively greater depth and detail, including receptor kinetics, molecular and cellular signaling and interactions, and the movement of molecules through membranes.
Being mostly non-invasive, bioimaging offers precise tracking of metabolites that can be used as biomarkers for disease identification, progress and treatment response. Bioimaging is thus a powerful tool for viewing the internal workings of the body and its diseases.
At Pharmidex we offer two systems for non-invasive in vivo imaging for both small rodents using the In-Vivo FX PRO and larger animals (pigs and sheep) using our other system.
Pharmidex Pharmaceutical Services has not received any reviews.
Pharmidex Pharmaceutical Services has not received any endorsements.